← Back to Search

Other

ANG-3777 for Hemodialysis

Phase 1
Waitlist Available
Led By Daniel K. Ries, MD
Research Sponsored by Angion Biomedica Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 and day 2
Awards & highlights

Study Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of a single-dose of ANG-3777 in subjects with renal failure receiving maintenance hemodialysis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 and day 2
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 and day 2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure the pharmacokinetic (PK) parameters of a single dose of ANG-3777 including, but not limited to: AUC(0-last) and AUC(0-inf)
Measure the pharmacokinetic (PK) parameters of a single dose of ANG-3777 including, but not limited to: Cmax
Measure the pharmacokinetic (PK) parameters of a single dose of ANG-3777 including, but not limited to: Tmax

Side effects data

From 2007 Phase 3 trial • 330 Patients • NCT00035815
62%
Depression
53%
Site reactions
33%
Respiratory failure
14%
Change in visual acuity
13%
Hypoglycemia
13%
Headache
11%
Thrombotic events
8%
Hepatotoxicity
6%
Abnormal blood chemistries (other than liver)
100%
80%
60%
40%
20%
0%
Study treatment Arm
IGF-1
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: ANG-3777Experimental Treatment1 Intervention
Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).

Find a Location

Who is running the clinical trial?

Angion Biomedica CorpLead Sponsor
11 Previous Clinical Trials
946 Total Patients Enrolled
Nucleus Network LtdOTHER
11 Previous Clinical Trials
490 Total Patients Enrolled
Daniel K. Ries, MDPrincipal InvestigatorNucleus Network Ltd
1 Previous Clinical Trials
16 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects
2021. "Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04958187.
All > Dialysis
~4 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top